Trial · NCT07891793
Late-Start Corifollitropin Alfa in Mild Ovarian Stimulation
NCT07891793, Not applicable, Completed, Assisting Nature
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Late-Start Corifollitropin Alfa in Mild Ovarian Stimulation. Trials, record NCT07891793. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891793
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Late-Start Corifollitropin Alfa in Mild Ovarian Stimulation
- NCT number
- NCT07891793
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 180 participants, actual
- Lead sponsor
- Assisting Nature
- Conditions
- Infertile Patient Undergoing ICSI Procedure
- Interventions
- Corifollitropin Alfa 150 μg, GnRH antagonist, Progesterone, Human Menopausal Gonadotropin (hMG)
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Mature (MII) Oocytes Retrieved per Initiated Stimulation Cycle | From initiation of ovarian stimulation through oocyte retrieval, up to 14 days. | The number of mature metaphase II (MII) oocytes obtained following ovarian stimulation, assessed at the time of oocyte retrieval. The outcome will be expressed as the number of MII oocytes per initiated stimulation cycle. Participants whose cycles are cancelled before oocyte retrieval or who have no mature oocytes retrieved will be assigned a value of zero. |
| Secondary | Total Number of Oocytes Retrieved per Initiated Stimulation Cycle | From initiation of ovarian stimulation through oocyte retrieval, up to 14 days. | The total number of oocytes obtained during transvaginal oocyte retrieval. The outcome will be expressed as the number of retrieved oocytes per initiated stimulation cycle. Participants whose cycles are cancelled before oocyte retrieval or who have no oocytes retrieved will be assigned a value of zero. |
| Secondary | Oocyte maturation rate | At oocyte retrieval, up to 14 days after initiation of ovarian stimulation. | The percentage of retrieved oocytes classified as mature metaphase II (MII) oocytes. The maturation rate will be calculated as the number of MII oocytes divided by the total number of retrieved oocytes, multiplied by 100. The analysis will include participants with at least one retrieved oocyte. |
| Secondary | Normal fertilization rate (2PN) | At fertilization assessment, 1 day after ICSI. | The percentage of injected mature oocytes demonstrating normal fertilization, defined by the presence of two pronuclei (2PN) following intracytoplasmic sperm injection (ICSI). The fertilization rate will be calculated as the number of normally fertilized (2PN) oocytes divided by the total number of injected MII oocytes, multiplied by 100. |
| Secondary | Blastocyst formation rate | From fertilization through day 6 of embryo culture. | The percentage of normally fertilized (2PN) embryos developing into blastocysts by day 6 of embryo culture. The blastocyst formation rate will be calculated as the total number of blastocysts formed by day 6 divided by the number of normally fertilized (2PN) oocytes, multiplied by 100. |
| Secondary | Number of Usable Blastocysts per Oocyte Retrieval | From fertilization through day 6 of embryo culture. | The total number of blastocysts considered suitable for embryo transfer or cryopreservation according to predefined laboratory morphological assessment criteria. Blastocysts will be assessed on days 5 and 6 of embryo culture. |
| Secondary | Total Supplementary Gonadotropin Consumption | From initiation of ovarian stimulation through ovulation triggering or cycle cancellation, up to 14 days. | The cumulative dose of supplementary human menopausal gonadotropin (hMG) administered during ovarian stimulation, expressed in International Units (IU). Supplementary hMG may be administered at a dose of 150 IU daily from cycle day 8 according to predefined hormonal and ultrasonographic response criteria. Participants who do not require supplementary hMG will be assigned a value of zero. The initial administration of 150 μg corifollitropin alfa will not be included in the calculation of supplementary hMG consumption. |
| Secondary | Clinical Pregnancy Rate per Embryo Transfer | From oocyte retrieval through clinical pregnancy assessment, up to 9 months. | The percentage of embryo transfer procedures resulting in clinical pregnancy. Clinical pregnancy is defined as ultrasonographic confirmation of at least one intrauterine gestational sac with fetal cardiac activity. All fresh and frozen embryo transfers involving embryos derived from the study stimulation cycle and performed within 6 months after oocyte retrieval will be included. The clinical pregnancy rate will be calculated as the number of embryo transfer procedures resulting in clinical pregnancy divided by the total number of embryo transfer procedures performed within the specified follow-up period, multiplied by 100. |
| Secondary | Ongoing Pregnancy Rate per Embryo Transfer | From oocyte retrieval through ongoing pregnancy assessment, up to 10 months. | The percentage of embryo transfer procedures resulting in an ongoing pregnancy. Ongoing pregnancy is defined as the presence of a viable intrauterine pregnancy with fetal cardiac activity at 12 completed weeks of gestation. All fresh and frozen embryo transfers involving embryos derived from the study stimulation cycle and performed within 6 months after oocyte retrieval will be included. The ongoing pregnancy rate will be calculated as the number of embryo transfer procedures resulting in ongoing pregnancy divided by the total number of embryo transfer procedures performed within the specified follow-up period, multiplied by 100. |
| Secondary | Live Birth Rate per Embryo Transfer | From oocyte retrieval through delivery, up to 18 months. | The percentage of embryo transfer procedures resulting in the delivery of at least one live-born infant. Live birth is defined as the complete expulsion or extraction of a fetus from the mother, irrespective of gestational age, showing evidence of life after birth. All fresh and frozen embryo transfers involving embryos derived from the study stimulation cycle and performed within 6 months after oocyte retrieval will be included. Multiple live-born infants resulting from a single embryo transfer procedure will be counted as one live birth event. The live birth rate will be calculated as the number of embryo transfer procedures resulting in at least one live birth divided by the total number of embryo transfer procedures performed within the specified follow-up period, multiplied by 100. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891793
GET https://conductscience.org/api/trials/v1/NCT07891793/registered